Bcr/Abl P210-pLEF Citations (5)
Originally described in: Activity of the Bcr GTPase-activating domain is regulated through direct protein/protein interaction with the Rho guanine nucleotide dissociation inhibitor.Kweon SM, Cho YJ, Minoo P, Groffen J, Heisterkamp N J Biol Chem. 2008 Feb 8;283(6):3023-30. Epub 2007 Dec 10. PubMed Journal
Articles Citing Bcr/Abl P210-pLEF
| Articles |
|---|
| MAPK15 mediates BCR-ABL1-induced autophagy and regulates oncogene-dependent cell proliferation and tumor formation. Colecchia D, Rossi M, Sasdelli F, Sanzone S, Strambi A, Chiariello M. Autophagy. 2015 Oct 3;11(10):1790-802. doi: 10.1080/15548627.2015.1084454. PubMed |
One reporter for in-cell activity profiling of majority of protein kinase oncogenes.
Gudernova I, Foldynova-Trantirkova S, Ghannamova BE, Fafilek B, Varecha M, Balek L, Hruba E, Jonatova L, Jelinkova I, Kunova Bosakova M, Trantirek L, Mayer J, Krejci P.
Elife. 2017 Feb 15;6. pii: e21536. doi: 10.7554/eLife.21536.
PubMed
Associated Plasmids |
| TPEN/TPGS (T2) combo dramatically reduces Philadelphia chromosome-positive pro-lymphoblastic B leukemia in BALB/c mice. Mendivil-Perez M, Jimenez-Del-Rio M, Velez-Pardo C. Med Oncol. 2022 Nov 9;40(1):15. doi: 10.1007/s12032-022-01873-y. PubMed |
| Reversible control of kinase signaling through chemical-induced dephosphorylation. Sun Y, Zhou R, Hu J, Feng S, Hu Q. Commun Biol. 2024 Aug 31;7(1):1073. doi: 10.1038/s42003-024-06771-9. PubMed |
| Autophosphorylation of oncoprotein TEL-ABL in myeloid and lymphoid cells confers resistance to the allosteric ABL inhibitor asciminib. Muratcioglu S, Eide CA, Hung CL, Gorday K, Sumpena E, Zuo W, Groves JT, Druker BJ, Kuriyan J. Sci Signal. 2025 Jul 15;18(895):eadt5931. doi: 10.1126/scisignal.adt5931. Epub 2025 Jul 15. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.